Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

Tanruprubart has received Fast Track and Orphan Drug designations, emphasizing its potential to transform the treatment landscape for GBS, a severe autoimmune disease affecting thousands globally.

The Task Force of the European Academy of Neurology and the Peripheral Nerve Society published updated guidelines in 2024 on the diagnosis and treatment of Guillain-Barré syndrome (GBS), which ...

and that there is a clear and urgent need for new and faster treatment options in GBS. This data offers meaningful insights to help advance the understanding of IgG in GBS and improve patient care." ...

Pune: A seven-and-half-year-old boy was discharged from Deenanath Mangeshkar Hospital on May 3 after battling a ...

He sees this moment as a promising one when there is potential to make advances in the treatment of GBS after decades without any significant developments. “GBS is an acute debilitating neuromuscular ...